Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease

PHASE4TerminatedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Type 2 Diabetes MellitusCardiovascular DiseaseHypercholesterolemia
Interventions
DRUG

Placebo

Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks

DRUG

Dehypotin

Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks

Trial Locations (1)

712

Nang Kuang Pharmaceutical Co., LTD, Tainan City

All Listed Sponsors
collaborator

National Taiwan University Hospital

OTHER

lead

Nang Kuang Pharmaceutical Co., Ltd.

INDUSTRY